{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:26:07Z","timestamp":1740108367736,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00228-021-03227-5","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:03:06Z","timestamp":1641859386000},"page":"565-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A genetic-based population PK\/PD modeling of methadone in Chinese opiate dependence patients"],"prefix":"10.1007","volume":"78","author":[{"given":"Dong","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoya","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6885-5898","authenticated-orcid":false,"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"3227_CR1","unstructured":"Institute of Medicine (1995) (US) Committee on Federal Regulation of Methadone Treatment; Rettig RA YA, editors. Federal regulation of methadone treatment. Washington (DC): National Academies Press (US) 5"},{"issue":"14","key":"3227_CR2","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","volume":"41","author":"CB Eap","year":"2002","unstructured":"Eap CB, Buclin T, Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41(14):1153\u20131193","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3227_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF03256276","volume":"12","author":"Y Li","year":"2008","unstructured":"Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S (2008) Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 12(2):109\u2013124","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"3227_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.7326\/0003-4819-137-6-200209170-00010","volume":"137","author":"MJ Krantz","year":"2002","unstructured":"Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS (2002) Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137(6):501\u2013504","journal-title":"Ann Intern Med"},{"issue":"4","key":"3227_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1465-3362.2010.00237.x","volume":"30","author":"S Mayet","year":"2011","unstructured":"Mayet S, Gossop M, Lintzeris N, Markides V, Strang J (2011) Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation? Drug Alcohol Rev 30(4):388\u2013396","journal-title":"Drug Alcohol Rev"},{"key":"3227_CR6","doi-asserted-by":"crossref","unstructured":"Kristensen K, Christensen CB, Christrup LL (1995) The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 56(2):PL45\u201350","DOI":"10.1016\/0024-3205(94)00426-S"},{"issue":"5","key":"3227_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","volume":"81","author":"CB Eap","year":"2007","unstructured":"Eap CB, Crettol S, Rougier JS et al (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81(5):719\u2013728","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3227_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000167043","volume":"113","author":"C Lin","year":"2009","unstructured":"Lin C, Somberg T, Molnar J, Somberg J (2009) The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 113(1):59\u201365","journal-title":"Cardiology"},{"issue":"1","key":"3227_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","volume":"108","author":"Y Chang","year":"2011","unstructured":"Chang Y, Fang WB, Lin SN, Moody DE (2011) Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 108(1):55\u201362","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"3227_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","volume":"108","author":"RA Totah","year":"2008","unstructured":"Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108(3):363\u2013374","journal-title":"Anesthesiology"},{"issue":"3","key":"3227_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1081\/ADA-100101879","volume":"25","author":"DA Wasserman","year":"1999","unstructured":"Wasserman DA, Korcha R, Havassy BE, Hall SM (1999) Detection of illicit opioid and cocaine use in methadone maintenance treatment. Am J Drug Alcohol Abuse 25(3):561\u2013571","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"4","key":"3227_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0376-8716(86)90097-9","volume":"18","author":"ML Stitzer","year":"1986","unstructured":"Stitzer ML, Bickel WK, Bigelow GE, Liebson IA (1986) Effect of methadone dose contingencies on urinalysis test results of polydrug-abusing methadone-maintenance patients. Drug Alcohol Depend 18(4):341\u2013348","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"3227_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2217\/pgs-2018-0017","volume":"19","author":"B Oueslati","year":"2018","unstructured":"Oueslati B, Moula O, Ghachem R (2018) The impact of OPRM1\u2019s genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review. Pharmacogenomics 19(8):741\u2013747","journal-title":"Pharmacogenomics"},{"issue":"6","key":"3227_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/FPC.0b013e328320a3fd","volume":"19","author":"A Doehring","year":"2009","unstructured":"Doehring A, Hentig N, Graff J et al (2009) Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics 19(6):407\u2013414","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"3227_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jchromb.2004.03.059","volume":"806","author":"HR Liang","year":"2004","unstructured":"Liang HR, Foltz RL, Meng M, Bennett P (2004) Method development and validation for quantitative determination of methadone enantiomers in human plasma by liquid chromatography\/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 806(2):191\u2013198","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3227_CR16","doi-asserted-by":"crossref","unstructured":"Gabriel S, Ziaugra L, Tabbaa D (2009) SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. Chapter 2:Unit 2 12","DOI":"10.1002\/0471142905.hg0212s60"},{"key":"3227_CR17","doi-asserted-by":"crossref","unstructured":"Fridericia LS (2003) The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann Noninvasive Electrocardiol 8(4):343\u2013351","DOI":"10.1046\/j.1542-474X.2003.08413.x"},{"key":"3227_CR18","doi-asserted-by":"crossref","unstructured":"Bauer RJ (2019) NONMEM Tutorial Part II: Estimation Methods and Advanced Examples. CPT Pharmacometrics Syst Pharmacol","DOI":"10.1002\/psp4.12422"},{"key":"3227_CR19","unstructured":"Radack KL, Rouan G, Hedges J (1986) The likelihood ratio. An improved measure for reporting and evaluating diagnostic test results. Arch Pathol Lab Med\u00a0110(8):689\u2013693"},{"issue":"6","key":"3227_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/j.1365-2125.2004.02079.x","volume":"57","author":"DJ Foster","year":"2004","unstructured":"Foster DJ, Somogyi AA, White JM, Bochner F (2004) Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57(6):742\u2013755","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"3227_CR21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s40262-016-0415-2","volume":"55","author":"C Csajka","year":"2016","unstructured":"Csajka C, Crettol S, Guidi M, Eap CB (2016) Population genetic-based pharmacokinetic modeling of methadone and its relationship with the QTc interval in opioid-dependent patients. Clin Pharmacokinet 55(12):1521\u20131533","journal-title":"Clin Pharmacokinet"},{"key":"3227_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.drugalcdep.2014.10.014","volume":"145","author":"G Bart","year":"2014","unstructured":"Bart G, Lenz S, Straka RJ, Brundage RC (2014) Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend 145:185\u2013193","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"3227_CR23","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bcp.13906","volume":"85","author":"T van Donge","year":"2019","unstructured":"van Donge T, Samiee-Zafarghandy S, Pfister M et al (2019) Methadone dosing strategies in preterm neonates can be simplified. Br J Clin Pharmacol 85(6):1348\u20131356","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3227_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/1097-0258(20010115)20:1<75::AID-SIM602>3.0.CO;2-C","volume":"20","author":"KG Kowalski","year":"2001","unstructured":"Kowalski KG, Hutmacher MM (2001) Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 20(1):75\u201391","journal-title":"Stat Med"},{"issue":"2","key":"3227_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2125.2011.04076.x","volume":"73","author":"J Yang","year":"2012","unstructured":"Yang J, He MM, Niu W et al (2012) Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. Br J Clin Pharmacol 73(2):268\u2013284","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"3227_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","volume":"52","author":"ZE Barter","year":"2013","unstructured":"Barter ZE, Tucker GT, Rowland-Yeo K (2013) Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet 52(12):1085\u20131100","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3227_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.drugalcdep.2011.01.004","volume":"117","author":"C Lin","year":"2011","unstructured":"Lin C, Detels R (2011) A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China. Drug Alcohol Depend 117(1):45\u201349","journal-title":"Drug Alcohol Depend"},{"key":"3227_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3389\/fphar.2019.00591","volume":"10","author":"XY Zhou","year":"2019","unstructured":"Zhou XY, Hu XX, Wang CC et al (2019) Enzymatic activities of CYP3A4 allelic variants on quinine 3-hydroxylation in vitro. Front Pharmacol 10:591","journal-title":"Front Pharmacol"},{"issue":"3","key":"3227_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/clpt.2008.215","volume":"85","author":"YS Kang","year":"2009","unstructured":"Kang YS, Park SY, Yim CH et al (2009) The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 85(3):312\u2013318","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3227_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","volume":"80","author":"S Crettol","year":"2006","unstructured":"Crettol S, Deglon JJ, Besson J et al (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80(6):668\u2013681","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3227_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/chir.10303","volume":"16","author":"JG Gerber","year":"2004","unstructured":"Gerber JG, Rhodes RJ, Gal J (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16(1):36\u201344","journal-title":"Chirality"},{"issue":"14","key":"3227_CR32","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.3748\/wjg.v13.i14.2100","volume":"13","author":"BY Xu","year":"2007","unstructured":"Xu BY, Guo LP, Lee SS et al (2007) Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World J Gastroenterol 13(14):2100\u20132103","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3227_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4103\/0022-3859.105439","volume":"58","author":"N Musa","year":"2012","unstructured":"Musa N, Zulkafli MI, Talib N, Mohamad N, Fauzi H, Ismail R (2012) Haplotypes frequencies of CYP2B6 in Malaysia. J Postgrad Med 58(4):235\u2013241","journal-title":"J Postgrad Med"},{"issue":"14","key":"3227_CR34","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/hmg\/ddn122","volume":"17","author":"O Levran","year":"2008","unstructured":"Levran O, O\u2019Hara K, Peles E et al (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 17(14):2219\u20132227","journal-title":"Hum Mol Genet"},{"issue":"5\u20136","key":"3227_CR35","first-page":"404","volume":"67","author":"SB Leavitt","year":"2000","unstructured":"Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P (2000) When, \u201cenough\u201d is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med 67(5\u20136):404\u2013411","journal-title":"Mt Sinai J Med"},{"issue":"4","key":"3227_CR36","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.273","volume":"91","author":"J Florian","year":"2012","unstructured":"Florian J, Garnett CE, Nallani SC, Rappaport BA, Throckmorton DC (2012) A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clin Pharmacol Ther 91(4):666\u2013672","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03227-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T08:03:00Z","timestamp":1647417780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03227-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"11 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}